1-3 of 3
Zev A. Wainberg
Close
Sort by
Journal Articles

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Clinical Trials & Observations
Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, Vivek Subbiah
Journal: Blood
Blood (2023) 141 (9): 996–1006.
https://doi.org/10.1182/blood.2021013658
Published: 2023
Includes: Supplemental data
Journal Articles

Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma

Vincent Ribrag, Jean-Marie Michot, Lara Igleias, Daniel Tan, Brigette Ma, Matteo Duca, Zev A. Wainberg, Yu Yun Fan, Naoka Suenaga, Yi Cheng, Clinton Lai, Tomoya Yokota
Journal: Blood
Blood (2021) 138 (Supplement 1): 1422.
https://doi.org/10.1182/blood-2021-147904
Published: 2021
Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 391.
https://doi.org/10.1182/blood-2018-99-113135
Published: 2018